Optimizing Treatment Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer
Host: Scott Kopetz, MD, PhD
Guest: Prof Eric Van Cutsem, MD, PhD
Guest: Josep Tabernero, MD, PhD
Dr. Scott Kopetz, Prof. Eric Van Cutsem, and Dr. Josep Tabernero engage in a panel discussion with a focus on the practice-changing initial and subsequently updated mature findings from the BEACON trial. These pivotal findings alter the standard of care for patients with BRAF V600E-mutated metastatic colorectal cancer following first-line failure. Find out what you need to know about the latest studies so you can provide the best care for your patients with this condition.
Additional downloadable slides will be available soon.